Fertin Pharma A/S
Fertin Pharma’s Parent Company Acquires MedCan Pharma - Allowing Entry into Fast-growing Market for Cannabinoid Products
VEJLE, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Claudio Bidco A/S (the “Parent Company
”), the parent company of Fertin Pharma A/S (“Fertin Pharma
”) has signed and closed the acquisition of MedCan Pharma A/S (“MedCan Pharma
”), a research organisation focusing on developing innovative products containing cannabinoids with a primary focus on the fast-growing market for medicated cannabis.
Headquartered in Vejle, Denmark, Fertin Pharma is the leading independent B2B developer and manufacturer of medicated chewing gum, primarily within Nicotine Replacement Therapy (“NRT ”), a pharmaceutical product used for withdrawal management in the process of tobacco cessation. Furthermore, Fertin Pharma has a wide portfolio of other medical chewing gum products as well as Nutraceutical products. In recent years, the company’s unparalleled expertise within chewing gum has been further expanded with a range of lozenges and products based on the innovative Zapliq® platform1 .
The acquisition will give MedCan Pharma access to Fertin Pharma’s strong capabilities within chewing gum and other oral delivery systems and form a unique platform for finalising the commercial development of medicinal cannabinoid products. MedCan Pharma will continue its wide range of existing dialogues with both large and specialty players in the cannabis industry and will be seeking new partnerships on a global scale through Fertin Pharma’s existing set-up.
The global market for pharmaceutical and medicinal use of cannabis is expected to grow into a multi-billion dollar market over the coming years as an increasing number of countries legalise products containing Cannabinoids for therapeutic purposes. Fertin Pharma, in combination with Medcan Pharma, is poised to take part in this growth.
If you want to learn more about Fertin Pharma and explore opportunities for collaboration, please visit www.fertin.com . In case of questions related to the acquisition of MedCan Pharma, please contact Søren Birn, CEO, Claudio Bidco A/S and Fertin Pharma A/S on +45 7215 1521.
1 Zapliq® is an innovative, patented delivery system invented by Fertin Pharma. Zapliq® is unique in its ability to transform from a solid dose format into a liquid in seconds. Zapliq® allows for high convenience, potentially faster on-set of action and interesting taste masking capabilities. Zapliq® can be used as a delivery system for both Rx, OTC and Nutraceutical products.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Apellis Pharmaceuticals, Inc.15.6.2019 16:02:13 CEST | Pressemeddelelse
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
VSBLTY, INC13.6.2019 10:12:00 CEST | Pressemeddelelse
VSBLTY CEO REPORTS ON COMPANY IMPLEMENTATION OF AI AND MACHINE LEARNING TECHNOLOGY
Juniper Networks13.6.2019 04:02:18 CEST | Pressemeddelelse
Juniper Networks Wins “Best of Show” Top Awards at Interop Tokyo 2019
SignalFx12.6.2019 15:01:16 CEST | Pressemeddelelse
SignalFx Raises $75 Million to Fuel Demand for its Cloud Monitoring Platform
Crown Bioscience12.6.2019 14:02:02 CEST | Pressemeddelelse
Crown Bioscience Announces Four New Preclinical NASH Models In Development
IHMA Inc12.6.2019 14:02:01 CEST | Pressemeddelelse
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum